“…The mean BCVA at 12 months was 0.39 ± 0.41 logMAR (∼20/50 Snellen, n = 43 eyes; 3 studies) across study arms administering anti-VEGF agents using a PRN regimen [10, 19, 21], 0.41 ± 0.30 logMAR (∼20/50 Snellen, n = 144 eyes, 3 studies) across arms using a T&E regimen [10, 17, 18], and 0.17 ± 0.28 logMAR (∼20/32 Snellen, n = 61 eyes, 3 studies) across arms using a fixed bimonthly regimen [17, 19, 21]. The mean improvement in BCVA from baseline was 0.08 ± 0.25 logMAR (mean follow-up = 12 months, n = 33 eyes, 2 studies) across study arms administering anti-VEGF agents using a PRN regimen [10, 19], 0.15 ± 0.26 logMAR (mean follow-up = 11.5 months, n = 270 eyes, 4 studies) across arms using a T&E regimen [10, 17, 18, 20], and 0.15 ± 0.21 logMAR (mean follow-up = 12 months, n = 38 eyes, 2 studies) across arms using a fixed bimonthly regimen [17, 19]. The mean RT at 12 months was 253.93 ± 110.71 μm ( n = 27 eyes, 2 studies) across study arms administering anti-VEGF agents using a PRN regimen [19, 21], 244.05 ± 83.48 μm ( n = 130 eyes, 2 studies) across arms using a T&E regimen [17, 18], and 238.60 ± 74.89 μm ( n = 61 eyes, 3 studies) across study arms using a fixed bimonthly regimen [17, 19, 21].…”